Search results

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

25 November 2020

NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZenec

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

25 November 2020

Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

18 November 2020

Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

18 November 2020

Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

18 November 2020

Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

18 November 2020

Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

16 December 2020

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

16 December 2020

Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

06 January 2021

Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

09 December 2020

Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)